ClinicalTrials.gov
ClinicalTrials.gov Menu

Detection of Plasma DNA in Non Small Cell and Small Cell Lung Cancer Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00213798
Recruitment Status : Completed
First Posted : September 21, 2005
Last Update Posted : August 30, 2011
Sponsor:
Information provided by:
University Hospital, Strasbourg, France

Brief Summary:
The majority of lung cancer patients have a tumor-derived genetic alteration in circulating plasma DNA that could be exploited as a diagnostic tool. The aim of this study is to evaluate if plasma DNA can be used as a valuable non invasive test to monitor disease progression without assessing the tumor.

Condition or disease Intervention/treatment Phase
Non-Small Cell Lung Carcinoma Small Cell Lung Cancer Procedure: Biopsy samples Not Applicable

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 200 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Screening
Official Title: Detection of Plasma DNA by Allelotyping in Non Small Cell and Small Cell Lung Cancer Patients. Evolution During Treatment and Follow-up.
Study Start Date : December 2003
Actual Study Completion Date : August 2011

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lung Cancer





Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Presence of lung tumor to use fiberoscopy or surgical intervention for diagnosis.
  • No lung instability.
  • Individuals give all informed consent

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00213798


Locations
France
Service de Pneumologie, Hôpital Lyautey
Strasbourg, France, 67000
Service de Chirurgie Thoracique, Hôpital Civil
Strasbourg, France, 67091
Service de Pneumologie, Hôpital Civil
Strasbourg, France, 67091
Service de Pneumologie, Hôpital de Hautepierre
Strasbourg, France, 67098
Sponsors and Collaborators
University Hospital, Strasbourg, France
Investigators
Principal Investigator: Michèle BEAU-FALLER, MD Service de Pneumologie, Hôpital de Hautepierre

Responsible Party: Emmanuel LAVOUE, Directeur Adjoint, University Hospital, Strasbourg, France
ClinicalTrials.gov Identifier: NCT00213798     History of Changes
Other Study ID Numbers: 2731
First Posted: September 21, 2005    Key Record Dates
Last Update Posted: August 30, 2011
Last Verified: August 2011

Keywords provided by University Hospital, Strasbourg, France:
Lung cancer
plasma DNA
allelotyping
follow-up
Prospective Study
Non-Small Cell Lung Cancer
Small Cell Lung Cancer

Additional relevant MeSH terms:
Lung Neoplasms
Small Cell Lung Carcinoma
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms